| Title: | Inflammation-metabolism-vascular & musculoskeletal multimorbidity: integrated epidemiology and genetics in UK Biobank |
| Lead Institution: | Hunan Provincial People?s Hospital (The First Affiliated Hospital of Hunan Normal University) |
| Principal investigator: |
Application 1082971
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
About
We will investigate how inflammatory and metabolic pathways jointly shape the development of multimorbidity across dermatological, cardiometabolic, vascular and musculoskeletal conditions. Using UK Biobank, our programme will address: (i) vascular outcomes, focusing on abdominal/thoracic aortic aneurysm and aortic dissection; (ii) inflammatory skin diseases (e.g., psoriasis, eczema/atopic dermatitis) as systemic phenotypes linked to metabolic risk; (iii) common metabolic disorders (type 2 diabetes, obesity, dyslipidaemia, hypertension); and (iv) major orthopaedic conditions (e.g., osteoarthritis and fragility fracture). We will integrate hospital and death registries with primary-care diagnoses and prescribing, and leverage imputed genotypes to construct polygenic risk scores (PRS) and pathway scores relevant to inflammation, lipid/glucose regulation and extracellular-matrix biology. Time-to-event and longitudinal models will quantify associations and test interactions between genetic susceptibility, blood-pressure traits (including variability), adiposity, lifestyle, and medications (antihypertensives, lipid-lowering therapy, antidiabetics including incretin-based agents). Where available, imaging-derived aortic measures will be analysed as intermediate phenotypes for mediation and effect-modification analyses. Sensitivity analyses will include exposure lags, active-comparator/new-user designs for drug effects, multiple imputation and quantitative bias analyses. All analyses will be undertaken on the UK Biobank Research Analysis Platform; no individual-level data will be downloaded. This integrated approach aims to identify shared mechanisms and produce actionable risk stratification to support earlier detection, targeted surveillance (e.g., aneurysm), and personalised prevention/therapy across co-existing diseases.1 Publication
| Pub ID | Title | Author(s) | Year | Journal |
|---|---|---|---|---|
| 19879 | Association of hematopoietic mosaic loss of chromosome Y with dermatitis and eczema risk: an analysis in a large-scale prospective cohort study | Yajia Li (+3) | 2026 | British Journal of Dermatology |
Enabling scientific discoveries that improve human health